ZEN 3694

Drug Profile

ZEN 3694

Alternative Names: ZEN-3694

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Zenith Epigenetics Corp
  • Class Antineoplastics
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Prostate cancer
  • Preclinical Haematological malignancies

Most Recent Events

  • 14 Dec 2016 Phase-I clinical trials in Prostate cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) (PO)
  • 15 Jun 2016 Phase-I clinical trials in Prostate cancer (Hormone refractory, Combination therapy, Metastatic disease) in USA (PO)
  • 01 Apr 2016 Phase-I clinical trials in Prostate cancer (Metastatic disease, Hormone refractory) in USA (PO) (NCT02705469)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top